MIR661

Summary

MIR661 (microRNA 661, HGNC:32917) is a microRNA gene on chromosome 8q24.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 724031 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32917
Approved symbol	MIR661
Name	microRNA 661
Location	8q24.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-661
Ensembl gene	ENSG00000207574
Ensembl biotype	miRNA
OMIM	613716
Entrez	724031
RNAcentral	URS00001C4680 — miRNA, 89 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384842

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384842 — 1 exons

Exon	Start	End
ENSE00001499849	143945191	143945279

Expression profiles

Bgee: expression breadth broad, 89 present calls, max score 86.52.

Top tissues by expression

89 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	86.52	gold quality
vermiform appendix	UBERON:0001154	78.84	gold quality
blood	UBERON:0000178	77.61	gold quality
endometrium	UBERON:0001295	75.00	gold quality
right adrenal gland cortex	UBERON:0035827	74.21	gold quality
gastrocnemius	UBERON:0001388	73.85	gold quality
monocyte	CL:0000576	73.69	gold quality
fundus of stomach	UBERON:0001160	72.58	gold quality
stomach	UBERON:0000945	72.04	gold quality
right adrenal gland	UBERON:0001233	72.03	gold quality
calcaneal tendon	UBERON:0003701	71.93	gold quality
right lobe of liver	UBERON:0001114	70.72	gold quality
adrenal gland	UBERON:0002369	70.69	gold quality
body of stomach	UBERON:0001161	70.66	gold quality
mucosa of transverse colon	UBERON:0004991	70.57	gold quality
liver	UBERON:0002107	70.41	gold quality
myometrium	UBERON:0001296	70.30	gold quality
body of pancreas	UBERON:0001150	70.24	gold quality
sural nerve	UBERON:0015488	69.95	gold quality
heart left ventricle	UBERON:0002084	69.76	gold quality
left adrenal gland	UBERON:0001234	69.37	gold quality
heart	UBERON:0000948	69.22	gold quality
left adrenal gland cortex	UBERON:0035825	68.84	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.64	gold quality
descending thoracic aorta	UBERON:0002345	68.62	gold quality
Ammon’s horn	UBERON:0001954	68.50	gold quality
tonsil	UBERON:0002372	68.34	gold quality
lower esophagus	UBERON:0013473	68.27	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.18	gold quality
right atrium auricular region	UBERON:0006631	68.16	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.23

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, MTA1

Literature-anchored findings (GeneRIF, showing 24)

• Results suggest that miR-661 be further investigated for therapeutic use in down-regulating the expression of MTA1 in cancer cells. (PMID:19584269)
• The miR-661 may either suppress or promote cancer aggressiveness, depending on p53 status. (PMID:24141721)
• Suggest miR-661 functions as a tumor promoter by targeting the INPP5J gene, and then promoting cell proliferation of ovarian cancer cells. (PMID:26282217)
• These results indicate that miR-661 can inhibit glioma cell proliferation, migration and invasion by targeting hTERT. (PMID:26585488)
• Five miRNAs were significantly upregulated in type 2 diabetes mellitus patients (p < 0.05) including miR-661, miR-571, miR-770-5p, miR-892b and miR-1303. Moreover, the levels of the five miRNAs were higher in patients with complications than in those without complications. (PMID:26831044)
• results indicate that miR-661 plays a tumor suppressor role in OS mediated by the downregulation of CYC1, suggesting a potential mechanism underlying cell death resistance in Osteosarcoma. (PMID:28391262)
• MiR661 expression level was significantly correlated with differentiation, tumor stage and lymph node metastasis of nonsmall cell lung cancer patients and miR661 acted as an oncogene in nonsmall cell lung cancer, at least in part through RUNX3 targeting. (PMID:28656235)
• MiR-661 promotes metastasis of non small cell lung cancer through RB/E2F1 signaling and epithelial-mesenchymal transition events. (PMID:28716024)
• Human blastocyst-secreted miR-661 reduces endometrial epithelial cell adhesion via downregulation of MDM2, regulating endometrial-blastocyst adhesion, and implantation. (PMID:28847363)
• MicroR661 overexpression in non-metastatic human CC cells induces an epithelial-to-mesenchymal transition phenotype, and a reduced tolerance to metabolic stress. (PMID:28981199)
• The findings of this study indicated that, in human glioma cells, the circRNA, hsa-circ-0012129 might act as a natural miR-661 sponge, and that miR-661 could have suppressive effects on the expression of circ-0012129. (PMID:29686222)
• The circ-UBAP2 was mainly observed in the cytoplasm and was capable of sponging miRNA-661 to increase the expression of the oncogene MTA1. (PMID:30314706)
• Changes in expression of lncRNA-GAS5, miRNA-661, miRNA-1202 and MMP9 in M2 macrophages are involved in varicose vein disease. (PMID:30558403)
• Study demonstrated that the expression of hsamiR6613p was downregulated and UbcH10 was upregulated in nonsmall cell lung cancer (NSCLC) tumors and NSCLC cell lines. Overexpression of hsamiR6613p decreased the expression of UbcH10. Mechanistically, hsamiR6613p induced cell cycle G2 arrest through regulation of spindle assembly checkpoint function. (PMID:30896844)
• High miR661 expression is associated with squamous cell carcinoma in Paranasal Sinus Neoplasms. (PMID:30991875)
• MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival. (PMID:31056984)
• Circ_RUSC2 upregulates the expression of miR-661 target gene SYK and regulates the function of vascular smooth muscle cells (PMID:31199889)
• The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer’s Disease. (PMID:33129241)
• Hsa_Circ_0001947/MiR-661/DOK7 Axis Restrains Non-Small Cell Lung Cancer Development. (PMID:34528912)
• MiR-770-5p, miR-661 and miR-571 expression level in serum and tissue samples of foot ulcer caused by diabetes mellitus type II in Iranian population. (PMID:34643918)
• CircPDE7B/miR-661 axis accelerates the progression of human keloid fibroblasts by upregulating fibroblast growth factor 2 (FGF2). (PMID:35079927)
• Hsa_circ_0103232 promotes melanoma cells proliferation and invasion via targeting miR-661/RAB3D. (PMID:35549813)
• Hsa_circ_0080608 Attenuates Lung Cancer Progression by Functioning as a Competitive Endogenous RNA to Regulate the miR-661/ADRA1A Pathway. (PMID:37820700)
• Circular RNA CircSATB2 facilitates osteosarcoma progression through regulating the miR-661/FUS-mediated mRNA of ZNFX1. (PMID:37984605)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.